SCHEMBL30774584

SCHEMBL30774584

COc1cccc(CC(=O)N2CCc3c(-c4ccc(C#N)cc4)cncc32)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 8/20 0.48
▸ EIF2AK3 Q9NZJ5 1/20 0.48
▸ UCHL1 P09936 3/20 0.42
▸ USP30 Q70CQ3 2/20 0.42
▸ RAB9A P51151 2/20 0.41
▸ PTGER4 P35408 1/20 0.41
▸ PTGER2 P43116 1/20 0.41
▸ SIGMAR1 Q99720 1/20 0.41
▸ EGLN2 Q96KS0 2/20 0.40
▸ MAPK13 O15264 1/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ NTRK1 P04629 1/20 0.40
▸ LCK P06239 1/20 0.40
▸ FYN P06241 1/20 0.40
▸ YES1 P07947 1/20 0.40
▸ LYN P07948 1/20 0.40
▸ RET P07949 1/20 0.40
▸ MET P08581 1/20 0.40
▸ HCK P08631 1/20 0.40
▸ FGR P09769 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30774348 0.89 SMN1; SMN2 (0.49) UCHL1USP30RAB9ACYP11B1CYP11B2
SCHEMBL30774383 0.88 RIPK1 (0.46) RIPK1EIF2AK3UCHL1USP30CYP11B1
SCHEMBL30774496 0.86 RIPK1 (0.45) RIPK1EIF2AK3UCHL1USP30EGLN2
SCHEMBL30774363 0.85 CYP11B2 (0.55) UCHL1USP30ABL1CYP11B1CYP11B2
SCHEMBL30773978 0.85 FAAH (0.43) RIPK1EIF2AK3RAB9ASIGMAR1EGLN2
SCHEMBL30774488 0.85 RIPK1 (0.48) RIPK1EIF2AK3UCHL1USP30NTRK1
SCHEMBL30774574 0.82 CYP11B2 (0.44) EIF2AK3UCHL1USP30CYP11B1CYP11B2
SCHEMBL30774527 0.81 CYP11B2 (0.44) EIF2AK3UCHL1USP30CYP11B1CYP11B2
SCHEMBL30774510 0.81 CYP11B2 (0.44) RIPK1UCHL1USP30CYP11B1CYP11B2
SCHEMBL30774460 0.81 CYP11B2 (0.44) RIPK1UCHL1USP30CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US claimed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP claimed
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US disclosed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP disclosed
WO-2024061371-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 广州威诺森医药科技有限公司 2024-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof STS, NR5A1, CYP21A2 RIPK1 3331/4885EIF2AK3 1947/4885UCHL1 1728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback